DECIPARTICLES
LIVE

Serial Number

98487663

Owner

Sapu Bioscience, LLC

Attorney

Craig W. Mueller

Filing Date

Apr 7, 2024

Add to watchlist:

No watchlists yet
View on USPTO

DECIPARTICLES Trademark

Serial Number: 98487663

DECIPARTICLES is a trademark filed by Sapu Bioscience, LLC on April 7, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Sapu Bioscience, LLC

302-308 Hennessy Road
Wanchai 12345 , HK

Entity Type: 16

Trademark Details

Filing Date

April 7, 2024

Registration Date

Not Registered

Published for Opposition

March 31, 2026

Goods & Services

Pharmaceutical preparations, namely, drug preparations comprising small particles for enhanced absorption and therapeutic effect for the treatment of cancer, including pancreatic cancer, melanoma, skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, kidney cancer, stomach cancer, ovarian cancer, cervical cancer, liver cancer, multiple myeloma, lymphoma, glioma, glioblastoma, diffuse midline glioma, brain or spinal cancer, CNS tumors, HIV-AIDS, myelodysplastic disease, leukemia, hypertension, epilepsy, seizures, schizophrenia, bipolar disorder, psychosis, depressive disorder, dementia, obsessive-compulsive disorder, Huntington's disease, Parkinson's disease, fungal infection, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hyperglycemia, diabetes, inflammatory disease, obesity, fever, pain, asthma, bronchospasm, bacterial infection, pneumonia, pulmonary hypertension, and malaria; Drug delivery agents in the form of pharmaceutical preparations comprising small particles that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, including pancreatic cancer, melanoma, skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, kidney cancer, stomach cancer, ovarian cancer, cervical cancer, liver cancer, multiple myeloma, lymphoma, glioma, glioblastoma, diffuse midline glioma, brain or spinal cancer, CNS tumors, HIV-AIDS, myelodysplastic disease, leukemia, hypertension, epilepsy, seizures, schizophrenia, bipolar disorder, psychosis, depressive disorder, dementia, obsessive-compulsive disorder, Huntington's disease, Parkinson's disease, fungal infection, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hyperglycemia, diabetes, inflammatory disease, obesity, fever, pain, asthma, bronchospasm, bacterial infection, pneumonia, pulmonary hypertension, and malaria

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 26, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 31, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 31, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 25, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 10, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 10, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 10, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 10, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 10, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 10, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 10, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 10, 2026 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 16, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 16, 2025 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 20, 2025 GNFN
FINAL REFUSAL E-MAILED
Aug 20, 2025 GNFR
FINAL REFUSAL WRITTEN
Aug 20, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 18, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 18, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 18, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 11, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 11, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 19, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 19, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 19, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 15, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 14, 2024 NWOS
NEW APPLICATION ENTERED
Apr 7, 2024 NWAP